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A Meta-Analysis of Randomized Trials for the
Treatment of Nonalcoholic Fatty
Liver Disease
Giovanni Musso,1 Roberto Gambino,2 Maurizio Cassader,2 and Gianfranco Pagano2
Nonalcoholic fatty liver disease (NAFLD) encompasses a histological spectrum ranging
from simple steatosis to nonalcoholic steatohepatitis (NASH). NAFLD carries a higher
risk of cardio-metabolic and liver-related complications, the latter being confined to
NASH and demanding specific treatment. We assessed the efficacy of proposed treatments
for NAFLD/NASH by reviewing reports of randomized controlled trials (RCTs) on online
databases and national and international meeting abstracts through January 2010. Pri-
mary outcome measure was histological improvement; secondary outcome was biochemi-
cal improvement; improvement in radiological steatosis was also evaluated. Two reviewers
extracted articles using predefined quality indicators, independently and in duplicate.
Main outcomes of randomized controlled trials (RCTs) were pooled using random-effects
or fixed-effects models. Publication bias was assessed by funnel plots. Forty-nine RCTs (30
in NASH) were included: 23 RCTs (22 in NASH, 1 in NAFLD) had post-treatment histol-
ogy. Most RCTs were small and did not exceed 1-year duration. Weight loss, thiazolidine-
diones (especially pioglitazone), and antioxidants were most extensively evaluated. Weight
loss was safe and dose-dependently improved histological disease activity in NASH, but
more than 50% of patients failed to achieve target weight loss. Thiazolidinediones
improved steatosis and inflammation but yielded significant weight gain. RCTs with anti-
oxidants yielded conflicting results and were heterogeneous with respect to type and dose
of drug, duration, implementation of lifestyle intervention. Among the other agents, pen-
toxifylline, telmisartan and L-carnitine improved liver histology in at least 1 RCT in
NASH; polyunsaturated fatty acid (PUFA) ameliorated biochemical and radiological
markers of NAFLD. Other approaches yielded negative results. Conclusion: Well-designed
RCTs of adequate size and duration, with histological endpoints, are needed to assess
long-term safety and efficacy of proposed treatments on patient-oriented clinical out-
comes. (HEPATOLOGY 2010;52:79-104)
N
onalcoholic fatty liver disease (NAFLD)
affects 30% of the general Western adult pop-
ulation.1 NAFLD ranges from simple steatosis
to nonalcoholic steatohepatitis (NASH), characterized
by steatosis plus necro-inflammation, which can only
be differentiated by liver biopsy. NASH can progress
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to cirrhosis and end-stage liver disease and is projected
to be the leading cause of liver transplantation by
2020; furthermore, emerging evidence suggests that
NAFLD overall is associated with an increased cardio-
metabolic risk.1 We systematically reviewed the evi-
dence in the treatment of NAFLD and NASH.
Patients and Methods
Data Sources and Searches
Databases searched through January 2010 were:
MEDLINE, Ovid MEDLINE In-Process, Cochrane
CENTRAL Register of Controlled Trials; Cochrane
Database of Systematic Reviews, Excerpta Medica
Database, Pubmed, clinicaltrials.gov, and American
Association for the Study of Liver Diseases/American
Gastroenterological Association/European Association
for the Study of the Liver/Digestive Disease Week
meeting abstracts, which were subjected to the same
assessment as regular articles. We contacted ten authors
to verify results and methodological quality of retrieved
articles (see Acknowledgment).
Search terms were: NASH, NAFLD, nonalcoholic
steatohepatitis, nonalcoholic fatty liver disease, fatty liver,
liver fat, steatosis, AST, ALT, GGT, aminotransferase,
liver enzymes, management, therapy, treatment, trial.
Study Selection
Inclusion criteria were English and non-English
articles with participants aged older than 12 years, of
any sex or ethnic origin with NAFLD/NASH, diag-
nosed on the basis of radiological/histological evidence
of fatty liver.
Exclusion criteria were nonhuman studies, non-
randomized trials, letters/case reports, studies enrolling
fewer than 10 subjects, articles not reporting outcomes
of interest or primary data (editorials, reviews), studies
using inadequate case definitions or enrolling second-
ary steatosis (for example, drug-induced, total paren-
teral nutrition-induced steatosis).
Outcome Measures. Primary outcome assessed was
histological response (number of patients with
improvement in the degree of steatosis, inflammation,
and fibrosis). When post-treatment histology was
unavailable, biochemical response (alanine aminotrans-
ferase [ALT] responses, reported in all trials, was
reported in the text; aspartate aminotransferase and
gamma-glutamyl transpeptidase responses, less com-
monly reported, were described in online-only figures),
and radiological response (improvement in steatosis by
ultrasound, computed tomography, nuclear magnetic
resonance/spectroscopy) were evaluated. The effect on
cardiometabolic risk profile and adverse events were
also evaluated.
Data Extraction and Quality Assessment
Data were extracted independently and in duplicate
by two authors (G.M., G.P.); discrepancies were
resolved by mutual discussion. The agreement between
the two reviewers for selection and validity assessment
of trials was scored by kappa coefficient.
The quality of randomized controlled trials (RCTs)
was assessed by the Cochrane Risk of Bias Tool, attrib-
uting 1 point to each item. Additionally we assessed if
sample size was calculated a priori (total score range:
0-9; Table 1).2 Meta-analyses following Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses guidelines were also included.3
Data Synthesis and Analysis
We used WinBUGS 1.4 (WinBUGS 1996-2003,
Imperial College of Science & MRC, UK). The analy-
sis was carried out according to the Cochrane Hand-
book of Systematic Reviews.2 Dichotomous variables
were presented as odds ratios with 95% confidence
interval (CI), continuous variables as weighted mean
differences with 95% CI. The fixed-effect model was
used, with significance set at P ¼ 0.05. Statistical het-
erogeneity was assessed using the I2 statistic: with I2
values of 50% or greater, we used a random-effects
model and explored individual study characteristics
and those of subgroups of the main body of evidence.
Sensitivity analysis was performed by removing one
study at a time and repeating the meta-analysis to
assess whether any one study significantly affected
pooled estimates. Additionally, we planned a priori
subgroup analysis according to the following criteria:
NASH versus NAFLD population, diabetic versus
nondiabetic population, treatment duration 1 year or
less versus greater than 1 year, RCTs testing different
drugs of the same class or different doses of the same
drug, addition or not of lifestyle intervention to drug,
and for each item of the Cochrane Risk-of-Bias Tool.
Publication biases were examined using funnel plots.
Results
The agreement between two reviewers for study
selection was 0.88 and for quality assessment of trials
was 0.90. The methodological quality of the 49 (30 in
NASH) RCTs included was as follows (Fig. 1; Table
1): 19 RCTs had a quality score less than 6, six had a
quality score of 6, 24 had a score of 7 or greater (low
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risk of bias). Allocation concealment and double-blind-
ing were adequate in 45% and in 69% of RCTs; an
intention-to-treat analysis was performed in 69% of
RCTs. Sample size was calculated a priori in 4 of 19
RCTs with negative results.
Twenty-two RCTs in NASH and 1 RCT in NAFLD
had post-treatment histology and were defined as high
quality (HQ); RCTs in NASH were examined sepa-
rately from trials in NAFLD, which may include
patients with simple steatosis and with NASH.
Weight Reduction Through Lifestyle and
Pharmacological Intervention
Trials in NASH. Three HQ RCTs (total 125 par-
ticipants; two RCTs with quality score 7) were
included.
The RCT by Promrat randomized 41 overweight
patients to 1 year of an intensive lifestyle intervention
program, similar to that implemented in the Look
AHEAD, or standard nutritional counseling.4 Com-
pared with standard counseling, the intensive lifestyle
intervention arm lost significantly more weight (mean
weight loss, 8.7% versus 0.5%), improved steatosis and
NAFLD activity score (NAS), a sum of steatosis and
necroinflammatory scores indicating overall disease ac-
tivity, and reversed NASH in 67% of participants (ver-
sus 20% of controls, P ¼ 0.02). Other histological fea-
tures did not significantly change. Only those patients
(39% of total) losing 7% or more body weight signifi-
cantly improved histological disease activity score
whereas the remaining patients showed nonsignificant
histological changes compared with controls.
Fig. 1. Evidence acquisition flow diagram.
Quality scores of included studies are
included as median, range. High quality (HQ)
RCTs are RCTs with post-treatment histology.
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Another RCT randomized 53 pediatric-adolescent
patients to lifestyle intervention alone or with antioxi-
dant vitamins E and C.5 After 24 months, weight loss
averaged 6.6% and 10.7%, respectively (P ¼ 0.9). Ste-
atosis, lobular inflammation, hepatocyte ballooning,
and NAS significantly improved in the two arms, and
NASH resolved in 71% versus 92% patients (P ¼
0.27), respectively. Homeostasis Model Assessment
(HOMA), plasma glucose, and lipids also significantly
improved.
The third RCT evaluated lifestyle intervention, alone
or with orlistat, in overweight patients.6 Compliance
to pharmacological treatment exceeded 80%; weight
loss averaged 8% with orlistat and 6% with placebo.
Both arms significantly and similarly improved steato-
sis, necroinflammation, and NAS. Patients losing 5%
or more weight improved steatosis, insulin resistance,
and plasma glucose, but only those subjects (41% of
total) losing 9% or more weight also improved necro-
inflammation and NAS.
These RCTs suggest that weight loss is safe and can
improve histological and metabolic parameters in
NASH. Whether the required weight loss to improve
histological disease activity is higher than that required
to improve steatosis and metabolic parameters needs
further confirmation.
Trials in NAFLD
Two RCTs (155 participants, quality score 6, 8)
assessed the effect of lifestyle intervention on NAFLD.
In diabetic patients enrolled in the RCT Look
AHEAD (abstract), 1 year of intensive lifestyle inter-
vention enhanced weight loss (8.2% versus 0.1%,
P ¼ 0.009), slightly improving magnetic res-
onance spectroscopy (MRS)-detected hepatic steatosis
(3.02% versus 1.45%, P ¼ 0.003) and hemoglo-
bin A1c levels compared with standard counseling.7
In a placebo-controlled RCTs evaluating 6 months
of orlistat plus lifestyle intervention,8 weight loss
approached that observed by Harrison et al.6; however,
ALT and ultrasonographic steatosis improved more
consistently with orlistat. Orlistat was safe and well
tolerated, with minor adverse gastrointestinal com-
plaints not requiring discontinuation of therapy.
Three RCTs (209 participants, quality score ranging
3-6) assessed the effect of physical activity alone in
Fig. 2. Forest plot of RCTs comparing the effect of drugs on histological steatosis in NASH.
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NAFLD. In the first (abstract), 6 months of moderate-
intensity aerobic exercise reduced MRS-detected he-
patic (2.5%, P ¼ 0.003 versus controls) and subcu-
taneous abdominal fat and hemoglobin A1c in obese
diabetic subjects, despite comparable changes in body
mass index, lean body mass, and total or visceral fat.9
In another RCT, 4 weeks of moderate-intensity aerobic
exercise reduced MRS-detected hepatic fat by 21% (P ¼
0.04 versus controls) and visceral adipose tissue compared
with controls. Body weight, HOMA, and plasma lipids
did not significantly change.10 Importantly, dietary habits
did not change throughout the study.
In the last, 3 months of increased physical activity
dose-dependently improved liver enzymes, abdominal
obesity, and metabolic abnormalities in 141 overweight
subjects, independent of weight changes.11
These 3 RCTs suggest that exercise per se improves
indices of hepatic steatosis independently of weight
Fig. 2. (Continued)
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loss. The optimal type and dose of exercise in NAFLD
are currently being investigated in one RCT (clinical-
trials.gov identifier NCT00771108).
Indications on the optimal nutrient dietary composi-
tion for NAFLD are sparse, deriving mostly from com-
parative analysis of observational studies. In one RCT
enrolling 22 obese glucose-intolerant NAFLD subjects,
11 weeks of a low-carbohydrate caloric restriction
induced comparable weight loss (7%), and hepatic
(42%) and intra-abdominal fat reduction, but
improved hepatic insulin sensitivity by nearly threefold
compared with a high-carbohydrate isocaloric reduc-
tion.12 This RCT suggests that caloric restriction is the
most important goal for improving hepatic steatosis in
NAFLD, but carbohydrate restriction may further ben-
efit glucose metabolism in glucose-intolerant patients.
Trials in NASH
Five HQ RCTs (354 participants, 4 RCTs with qual-
ity score 7) assessed the effect of 6 to 24 months of
pioglitazone (four trials) or rosiglitazone (one RCT) on
liver histology in NASH.13-17 Pooled results of RCTs
showed that TZDs improved histological steatosis and
inflammation but not fibrosis (Figs. 2-4). Heterogeneity
was low for all assessed outcomes, suggesting a consist-
ent drug effect size across studies. Presence of diabetes,
the implementation of lifestyle intervention, different
drug dose, or trial duration did not affect results. No
significant publication bias was detected.
TZDs consistently improved hepatic, muscle, and
adipose tissue insulin resistance,13,14,18 and reduced
plasma glucose and hemoglobin A1c in glucose-intol-
erant subjects.14-16 Pioglitazone lowered plasma triglyc-
eride in glucose-intolerant subjects, but rosiglitazone
worsened total and low-density lipoprotein choles-
terol.16 Only one RCT reported the impact of TZDs
on blood pressure, with nonsignificant effects.15
Two RCTs evaluated the predictors of histological
response to TZDs: in the Fatty Liver Improvement
with Rosiglitazone Therapy (FLIRT), absence of diabe-
tes, a higher baseline serum adiponectin, and severe
steatosis predicted histological response.16 In another
RCT,14 histological response was similar between dia-
betic and nondiabetic subjects, whereas increased adi-
ponectin levels and adipocyte insulin sensitivity pre-
dicted histological improvement.18
The most common side effects were weight gain of
2-5 kg (66%-75% of patients), and lower extremity
Fig. 3. Forest plot of RCTs comparing the effect of drugs on histological inflammation in NASH.
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edema (4%-10%), the latter often causing treatment
discontinuation. Weight gain occurred despite lifestyle
intervention, which was implemented in all but the
FLIRT trial. Dropout rate ranged 4%-18% of
patients.
Because of the short trial duration, there was no
report of congestive heart failure, bone fractures, or
increased cardiovascular mortality, but the benefit-
safety profile of overall and single TZDs, as well as
eventual benefit on hepatic fibrosis, warrant assessment
in larger RCTs of longer duration.
The effects of TZD discontinuation were evaluated
in an extension of two small uncontrolled trials. In the
first, NASH and associated metabolic abnormalities
relapsed 1 year after discontinuing pioglitazone.19 In
the second, subjects achieving and maintaining lifestyle
changes and weight loss displayed sustained histologi-
cal and metabolic benefit 37 months after TZD
discontinuation.20
The effect of prolonged therapy with TZDs is
unknown, because most RCTs lasted 12 or fewer
months. Two trials evaluated the effects of TZD
Fig. 3. (continued)
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treatment for up to 2 and 3 years, respectively. In the
open-label FLIRT-2, patients completing the FLIRT
trial were placed on rosiglitazone for 2 additional years:
despite a continued improvement in insulin sensitivity
and aminotransferases, rosiglitazone did not further
improve liver histology.21 The ‘‘Pioglitazone Versus Vita-
min E Versus Placebo for the Treatment of Nondiabetic
Patients with NASH’’ trial (abstract at American Associa-
tion for the Study of Liver Diseases 2009), randomized
247 nondiabetic patients to 2 years of either pioglitazone,
vitamin E, or placebo. Lifestyle intervention was imple-
mented in all arms. Compared with placebo, pioglitazone
improved insulin sensitivity, steatosis, and inflammation,
and reversed NASH in 50% of patients versus 25% of
placebo-treated subjects (P ¼ 0.0008), but the primary
endpoint (NAS improvement by 2 or more points and
no worsening of fibrosis) was achieved by only 34% of
patients on pioglitazone versus 19% of patients on pla-
cebo (P ¼ 0.04).22,23
These trials suggest that long-term therapy with
TZDs may be required for sustained histological
improvement but offer no additional histological bene-
fit. Furthermore, improving insulin sensitivity may not
be sufficient for improving liver injury, and other ther-
apeutic approaches might be warranted for a durable
control of disease activity in NASH.
Trials in NASH
In four HQ RCTs (115 participants, two RCTs
with quality score >7), 6-12 months of metformin
plus lifestyle intervention did not improve liver histol-
ogy or aminotransferases, compared with lifestyle
Fig. 4. Forest plot of RCTs comparing the effect of drugs on histological fibrosis in NASH.
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intervention alone, independently of dose, treatment
duration, or diabetic state17,24-26 (Figs. 2-5). No publi-
cation bias was detected.
Trials in NAFLD
Two RCTs (144 participants, quality score <7) eval-
uated the effect of metformin on radiological and
biochemical indices of NAFLD.27,28 In one RCT, met-
formin normalized aminotransferases in 69% versus
31% of the diet group (P ¼ 0.003). In the other
RCT, biochemical and radiological improvement was
nonsignificant compared with diet þ exercise.
Overall, when added to lifestyle intervention, metfor-
min enhanced weight loss (mean weight loss, 4.3%-
7.9%) and improved insulin sensitivity and plasma glu-
cose levels: the latter effects were most consistent in dia-
betic patients and outweighed the magnitude of weight
loss.25,28 The plasma lipid profile did not significantly
change. Metformin was safe and well-tolerated, with gas-
trointestinal intolerance being the most common adverse
effect, not usually requiring discontinuation of therapy.
Despite its weight-losing and insulin-sensitizing proper-
ties, the effects of metformin on liver histology warrant
further evaluation in larger and longer RCTs.
Insulin-Sensitizers: Thiazolidinediones vs.
Metformin or vs. a Combination of Both Drugs
Trials in NASH. Two open-label HQ RCT (113
participants, quality score <6, one in abstract form)
compared the combination of rosiglitazone plus met-
formin versus each agent alone in NASH.29,30 After
1 year, steatosis and necroinflammation significantly
improved with rosiglitazone, but not with metformin;
the combination of both enhanced weight loss over
rosiglitazone alone but conferred no additional benefit
on liver histology and glucose metabolism.
Fig. 4. (continued)
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Trials in NAFLD. In a small RCT on diabetic
NAFLD patients, rosiglitazone reduced hepatic fat by
sevenfold compared with metformin (P ¼ 0.003), an
effect closely correlating with increased adiponectin
levels. Both drugs improved hepatic insulin sensitivity,
whereas peripheral insulin sensitivity increased only
with rosiglitazone.31
Lipid-Lowering Drugs
N-3 Polyunsaturated Fatty Acids (PUFA). In three
RCTs (209 participants, quality score < 7), PUFAs
ameliorated aminotransferases and radiological steatosis
in NAFLD (Fig. 5). Steatosis by MRS35 or ultrasonog-
raphy33,34 resolved in 20%-64% of cases. However,
ultrasonography is a qualitative, operator-dependent
technique and misses steatosis of lower grade (involving
< 33 % hepatocytes), making it hard to compare ultra-
sonographic with MRS trails.32-35 An improvement in
hypertriglyceridemia and insulin resistance was also
observed. Overall, PUFAs were well tolerated, with
minor gastrointestinal symptoms. The heterogeneity in
population, treatment duration, doses, methods to
assess radiological outcomes, and the lack of post-treat-
ment histology prevent any definitive conclusion
Three RCTs (clinicaltrials.gov identifier: NCT-
00323414, NCT00681408, NCT00760513) are eval-
uating PUFA in NASH.
Fibrates
Trials in NASH. In one RCT (quality score 8),
fibrates had no significant benefit on histological, bio-
chemical, or radiological outcome.36
Statins
The antioxidant and anti-inflammatory properties,
the frequent coexistence of NAFLD and dyslipidemia,
Fig. 5. Forest plot of comparison of RCTs comparing the effects of drugs on ALT levels in NAFLD.
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and the increased cardiovascular risk of these patients
make statins an attractive therapeutic tool in NAFLD.
Despite these premises, data on statin efficacy in
NAFLD are sparse because of the feared hepatotoxicity
of these drugs. A meta-analysis of 13 large trials showed
no increase in liver enzymes with statins.37 Further-
more, patients with hepatic steatosis do not seem at
increased risk for statin hepatotoxicity.38 On this basis,
the Liver Expert Panel stated that statins can be safely
used in patients with NAFLD, and routine liver enzyme
monitoring is not warranted in this population.39
Trials in NASH. In a small HQ RCT, 1 year of
simvastatin was safe but did not improve liver histol-
ogy (Table 1; Figs. 2-4).40
Trials in NAFLD. An RCT (quality score 8)
randomized 186 hyperlipidemic NAFLD patients to 12
months of lifestyle advice plus atorvastatin, fenofibrate,
or a combination of both (Table 1; Fig. 5).41 Despite a
consistent weight loss (11-13%) in all arms, biochemi-
cal plus ultrasonographic regression of NAFLD was sig-
nificantly higher with atorvastatin, alone or in combina-
tion, than with fenofibrate. Weight loss greater than
4% and concomitant use of orlistat or metformin inde-
pendently predicted treatment response.
The effects of statin exposure on liver histology over
10-16 years in 68 patients with NAFLD were retro-
spectively reviewed.42 Despite a higher baseline risk
profile for liver disease progression, patients on statin
improved liver steatosis and slowed fibrosis progression
compared with controls.
Probucol
Trials in NAFLD. Probucol, a lipophilic lipid-
lowering drug with strong antioxidant activity,
Fig. 5. (continued)
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Fig. 5. (continued)
significantly improved aminotransferases (with normal-
ization in 50% of patients) in a small RCT (quality
score 8).43 Although generally well tolerated, probucol
significantly reduced high-density lipoprotein choles-
terol levels, raising safety concern in patients at high
cardiovascular risk.
In summary, further large, prospective, placebo-con-
trolled trials with histological endpoints are warranted
before any firm conclusion can be drawn on the effec-
tiveness of lipid-lowering drugs in NAFLD/NASH.
Ursodeoxycholic Acid
Trials in NASH. Pooled results of three RCTs (340
participants, quality score 8) revealed marginally signifi-
cant benefit of ursodeoxycholic acid (UDCA) on liver
enzymes, the effect being entirely explained by the
high-dose UDCA RCT (Fig. 5).45-47 Two of these
RCTs assessed post-treatment-histology, finding no ben-
efit over placebo, but the effect of high-dose UDCA on
liver histology is unknown (Figs. 2-4; Table 1).
Trials in NAFLD. In three RCTs (113 participants,
1 RCT with quality score 7), UDCA for 1.5 to 6
months did not significantly improve ALT levels or ra-
diological steatosis47-49 (Fig. 5, Table 1).
Overall, no benefit on metabolic parameters was
observed with UDCA. Minor gastrointestinal effects
(diarrhea, motility disorders) occurred in up to 45%
of subjects on high-dose UDCA.
Antioxidants
The proposed pathogenetic role of oxidative stress
in NAFLD/NASH prompted evaluation of different
antioxidants, including vitamins C and E, methyl
donors (betaine) aiming at restoring reduced hepatic
glutathione stores, silymarin and silybin, free radical
scavengers with antifibrotic activity, and Viusid, a
nutritional supplement with different antioxidant
molecules.
Trials in NASH. Eight RCTs (508 participants,
quality score ranging 3-9) evaluated antioxidants in
NASH, with overall no significant benefit on liver
enzymes5,45,50-54 (Fig. 5; Supporting Figs. 1, 2).
Pooled results of the five HQ RCTs (quality score
8) showed no histological benefit with antioxidants.
However, heterogeneity of these studies was high with
respect to type and dose of drug, population (pediatric
versus adult), treatment duration, and addition of life-
style intervention. Heterogeneity was entirely explained
by the two placebo-controlled RCTs with positive
results (Figs. 2-4): in the Dufour study, 2 years of
UDCA þ vitamin E significantly improved histological
steatosis compared with double placebo. In the Piogli-
tazone Versus Vitamin E Versus Placebo for the Treat-
ment of Nondiabetic Patients with NASH trial,23
vitamin E improved steatosis, ballooning, and inflam-
mation (Figs. 2-4) and reversed NASH in half of the
patients versus 25% patients on placebo. The primary
endpoint was reached by 43% of patients with vitamin
E versus 34% of patients on pioglitazone and 19% of
patients on placebo (P ¼ 0.001 vitamin E versus pla-
cebo; P ¼ 0.23 vitamin E versus pioglitazone). In
these RCTs, no significant change in body weight or
insulin sensitivity occurred with antioxidants.
Trials in NAFLD. Four RCTs (362 participants,
one RCT with quality score 7) assessed antioxidants
in NAFLD.27,49,55,56 Pooled analysis of RCTs showed
significant ALT improvement with vitamin E; betaine
and silybin significantly improved ultrasonographic ste-
atosis as well (Fig. 5). In the HQ RCT assessing Viu-
sid plus lifestyle intervention,56 both arms lost 11%
body weight and improved steatosis and NAS com-
pared with baseline, but histological improvement was
more consistent with Viusid. No significant metabolic
effect or adverse event was observed with antioxidants.
No publication bias was detected.
The extreme heterogeneity of RCTs prevents any
firm conclusion on the effect of antioxidants in
NAFLD/NASH. Whether the histological benefit of
vitamin E may appear after 2 or more years of treat-
ment23,45 or may be enhanced by weight loss56
requires confirmation. Long-term safety of vitamin E
is also an issue, because doses of 400 IU/day or higher
have been associated with an increased all-cause
mortality.57
Anti-Tumor Necrosis Factor Alpha
Agents (Pentoxifylline)
Trials in NASH. In three small placebo-controlled
RCTs (75 participants, two with quality score 7) 3
to 12 months of pentoxifylline significantly improved
ALT58-60 (Fig. 5). In the only HQ RCT, 12 months of
pentoxifylline significantly improved hepatocyte bal-
looning and NAS, and decreased hepatic Bip gene
expression, an indicator of endoplasmic reticulum stress,
compared with placebo (Figs. 2-4). Body mass index,
HOMA score, serum adiponectin, and tumor necrosis
factor alpha were unchanged in either arm.
Overall, the drug was well-tolerated, without major
adverse events.
Two RCTs (clinicaltrials.gov NCT00590161, NCT-
00681733) are evaluating pentoxifylline in NASH.
100 MUSSO ET AL. HEPATOLOGY, July 2010
Antihypertensive Drugs
Trials in NASH. An HQ RCT (quality score 7)
randomized 54 hypertensive NASH patients to 20
months of valsartan or telmisartan (an angiotensin re-
ceptor blockers with PPAR-c-modulating activity).61
Both agents improved steatosis; telmisartan signifi-
cantly improved ballooning, lobular inflammation, and
fibrosis compared with valsartan (Figs. 2-4). Telmisar-
tan significantly reduced insulin resistance, plasma tri-
glycerides, and total cholesterol, whereas the blood
pressure-lowering effects were similar with either agent.
Currently, telmisartan is the only agent that improved
fibrosis in NASH: whether the combination of PPAR-
c and angiotensin receptor blockers activity of telmi-
sartan may mediate its extensive metabolic and histo-
logical benefits awaits confirmation in larger RCTs.
Endocannabinoid Receptor Antagonists
Trials in NAFLD. The effect of rimonabant on com-
puted tomography-assessed steatosis was assessed in
abdominally obese, dyslipidemic subjects with NAFLD
from the ADAGIO-Lipids trial (quality score 7).62 Rimo-
nabant reversed computed tomography-assessed steatosis
in 48% of patients versus 19% on placebo (P ¼ 0.03) and
significantly decreased aminotransferases, abdominal/vis-
ceral/subcutaneous fat, blood pressure, plasma lipopro-
teins, and C-reactive protein. Although patients with a his-
tory of depression were excluded, adverse effects led to
discontinuation of the drug in 13.8% of cases and
included gastrointestinal, depressive (2.0% versus 1.3% of
placebo), and anxiety disorders (2.2% versus 1.0%).
Whereas the benefit of rimonabant on cardiometabolic
profile and hepatic steatosis emerged, its safety and histo-
logical benefit in NASH are unknown. Concern about
depression, anxiety, and suicidal risk led the Food and
Drug Administration to deny drug approval in the United
States.
L-Carnitine
Trials in NASH. In an HQ RCT (quality score 9),
L-carnitine, a modulator of mitochondrial FFA trans-
port and oxidation, improved steatosis, NAS, and ami-
notransferases when added to lifestyle intervention for
6 months (Figs. 2-5).
L-carnitine was well tolerated and also improved
also HOMA, plasma glucose, and total and low-den-
sity lipoprotein-cholesterol compared with placebo.63
Bariatric Surgery
The rationale, efficacy, and safety of bariatric surgery
(BS) in 15 studies (766 paired liver biopsies) have
been systematically reviewed.64 Overall, BS was safe,
steatosis resolved in 91.6% (95% CI: 82.4%-97.5%),
steatohepatitis improved in 81.3% (61.9%-94.9%), fi-
brosis in 65.5% (38.2%-88.1%) of cases; NASH
resolved in 69.5% (42.4%-90.8%) of cases. However,
most studies were retrospective or observational, with
different lengths of follow-up, and some showed lim-
ited or no improvement in moderate to advanced fi-
brosis.65 In a recent 5-year prospective study on 381
subjects without advanced liver disease, although stea-
tosis, ballooning, and NAS improved significantly and
NASH resolved in 48% of cases, fibrosis worsened
slightly but significantly (fibrosis score was 1 or less in
more than 95% of patients after BS).66 Most of the
improvement occurred within 1 year, and the persist-
ence of insulin resistance at 1 year, rather than the
degree of weight loss, predicted lack of histological
response at 5 years.66 Therefore, although promising,
long-term effects of BS warrant prospective assessment
in homogeneous well-designed trials.
Discussion
Our analysis highlights the limitations of available
evidence for the treatment of NAFLD. Fifty-three per-
cent of RCTs assessed biochemical or radiological stea-
tosis, lacking post-treatment histology. Liver enzymes
and even steatosis spontaneously fluctuate over time in
NAFLD, and their improvement may simply reflect
‘‘regression to the mean’’ rather than treatment efficacy,
especially when patients are selected on the basis of ele-
vated liver enzymes. Furthermore, aminotransferases
and hepatic steatosis often do not parallel the course of
necroinflammation and fibrosis in NASH, improving
over time whereas necroinflammation and fibrosis
remain stable or progress.14-16,44,46 Only 21% of nega-
tive RCTs reported a priori sample size calculation,
which limits their negative predictive power. Finally, the
short duration of trials, not exceeding 2 years, prevents
any conclusion on long-term efficacy and safety of pro-
posed treatments; neither do they let us know whether
the observed histological and metabolic improvement
will translate into a clinical benefit in terms of liver-
related and cardiometabolic morbidity and mortality.
Given these premises, it is clear that available data
represent clues for future research and trial design,
rather than providing the basis for evidence-based clin-
ical recommendations.
Available RCTs suggest that weight loss is safe and
may dose-dependently improve histological disease activ-
ity and associated cardiometabolic risk factors in NASH:
a 5% weight loss improved steatosis and associate
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metabolic parameters, but higher degrees of weight loss
were required to ameliorate necroinflammation and over-
all disease activity. Future trials need to confirm these
dose-dependent effects and to assess whether an upper
threshold weight loss exists beyond which little histologi-
cal improvement occurs. A gradual weight loss (in other
words, <1.6 kg/week) would also be advisable, because
faster weight loss has exacerbated liver injury.67 Long-
term durability of achieved benefits and patient adherence
to weight-losing regimens are also a concern, because
only approximately 40% of patients achieved target
weight loss, even in those trials implementing multidisci-
plinary lifestyle interventions and behavioral therapy.4
Increasing evidence also suggests regular physical ac-
tivity per se reduces liver fat, independently of its
weight-losing effects, and also may protect NAFLD
patients against the development of diabetes.68
Exercise implementation into lifestyle programs
enhanced prolonged weight loss and proved more sus-
tainable over time than dietary intervention alone in
NAFLD-associated metabolic disorders,69 and the
effect of physical activity on liver histology in NASH
warrant further evaluation. Another major field of
research regards the optimal dietary nutrient composi-
tion for NASH, for which we found only one RCT
without histological data.
For patients with NASH unable to achieve or main-
tain lifestyle-induced weight loss, pharmacological treat-
ment could be considered. Currently, no specific phar-
macological treatment outside clinical trials can be
recommended, for the limitations discussed. TZDs
(mainly pioglitazone) and antioxidants have been most
extensively evalutated in HQ RCTs: whereas TZDs con-
sistently improved steatosis and inflammation, RCTs
with antioxidants were extremely heterogeneous and
yielded conflicting results, showing histological benefit
over 2 years or when implemented with weight-losing
regimens.23,45,56 However, long-term efficacy and safety
of TZDs are unknown, and not all patients respond to
TZDs. Only a few RCTs16,18 evaluated predictors of
response to pharmacological treatment: future trials
should address these issues, individuating clinical predic-
tors of response, to individualize therapy to the patient’s
clinical characteristics. The results of recent RCTs sug-
gest that therapeutic strategies other than insulin sensi-
tizers also may be effective in NASH23,60,61 and that a
combination therapy targeting multiple mechanisms
involved in the pathogenesis of NASH may be required.
Future trials need to assess, in particular, whether imple-
menting effective weigh-loss regimens with drugs has
synergistic benefits on liver histology.56,63
With the exception of telmisartan,61 available treat-
ments show no consistent benefit on hepatic fibrosis;
this may be attributable to an actual ineffectiveness of
proposed treatments, to a short trial duration, or to the
inclusion of subjects with mild degrees of fibrosis. Lon-
ger follow-up will tell whether improvement of inflam-
matory changes may favorably affect clinical outcomes,
because inflammation at initial biopsy independently
predicted fibrosis progression in NASH over 5 years.70
Clearly, future RCTs need to have histological end-
points, to have adequate power and duration, and to
enroll patients with the whole spectrum of fibrosis
severity; a longer duration will also allow the assess-
ment of long-term safety, durability, and benefits of
proposed treatments on patient-oriented outcomes,
including liver-related (for example, cirrhosis, liver
failure, hepatocellular carcinoma), cardiovascular, and
metabolic morbidity, which all contribute to the bur-
den of NAFLD.
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